Francine Durocher

List of Publications by Year
in descending order

247	19,635	15466 65	14156 128
papers	citations	h-index	g-index

252	252	252	20562
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
2	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	9.4	960
3	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
4	Breast Cancer Risk Genes â€" Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	13.9	532
5	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
6	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	9.4	513
7	A candidate prostate cancer susceptibility gene at chromosome 17p. Nature Genetics, 2001, 27, 172-180.	9.4	504
8	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
9	Is dehydroepiandrosterone a hormone?. Journal of Endocrinology, 2005, 187, 169-196.	1.2	417
10	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genetics in Medicine, 2019, 21, 1708-1718.	1.1	415
11	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
12	Genome-wide association studies identify four ER negativeâ€"specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	9.4	374
13	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, 47, 1294-1303.	9.4	357
14	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
15	Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nature Genetics, 1994, 8, 392-398.	9.4	313
16	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€"negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
17	DHEA and Its Transformation into Androgens and Estrogens in Peripheral Target Tissues: Intracrinology. Frontiers in Neuroendocrinology, 2001, 22, 185-212.	2.5	307
18	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289

#	Article	IF	Citations
19	17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. Journal of Molecular Endocrinology, 1999, 23, 1-11.	1.1	284
20	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 126-135.	1.1	278
21	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
22	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	2.6	257
23	The emergence of an ethical duty to disclose genetic research results: international perspectives. European Journal of Human Genetics, 2006, 14, 1170-1178.	1.4	254
24	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
25	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
26	RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	2.6	217
27	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	2.6	201
28	The Extent of Linkage Disequilibrium in Four Populations with Distinct Demographic Histories. American Journal of Human Genetics, 2000, 67, 1544-1554.	2.6	192
29	Effect of Chest X-Rays on the Risk of Breast Cancer Among BRCA1/2 Mutation Carriers in the International BRCA1/2 Carrier Cohort Study: A Report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaboratorsâ€™ Group. Journal of Clinical Oncology, 2006, 24, 3361-3366.	0.8	188
30	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	9.4	184
31	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology, 2020, 17, 687-705.	12.5	178
32	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
33	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.4	169
34	EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 51-84.	1.2	157
35	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
36	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152

#	Article	IF	Citations
37	(S)-(+)-4-[7-(2,2-Dimethyl-1-oxopro- poxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]- phenyl 2,2-Dimethylpropanoate (EM-800):Â A Highly Potent, Specific, and Orally Active Nonsteroidal Antiestrogen. Journal of Medicinal Chemistry, 1997, 40, 2117-2122.	2.9	143
38	A Combined Genomewide Linkage Scan of 1,233 Families for Prostate Cancerâ€“Susceptibility Genes Conducted by the International Consortium for Prostate Cancer Genetics. American Journal of Human Genetics, 2005, 77, 219-229.	2.6	138
39	Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 601-610.	1.1	130
40	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
41	Role of 17Î²-Hydroxysteroid Dehydrogenases in Sex Steroid Formation in Peripheral Intracrine Tissues. Trends in Endocrinology and Metabolism, 2000, 11, 421-427.	3.1	124
42	Linkage Analysis of Chromosome 1q Markers in 136 Prostate Cancer Families. American Journal of Human Genetics, 1998, 62, 653-658.	2.6	123
43	p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6. Nucleic Acids Research, 1999, 27, 2722-2729.	6.5	122
44	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
45	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Medicine, 2016, 13, e1002105.	3.9	118
46	Breast Cancer Treatments: Updates and New Challenges. Journal of Personalized Medicine, 2021, 11, 808.	1.1	108
47	Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Human Molecular Genetics, 1996, 5, 835-842.	1.4	107
48	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	1.5	105
49	No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis, 1999, 20, 2131-2135.	1.3	103
50	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	1.4	99
51	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	2.6	98
52	Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenetics and Genomics, 2001, 11, 325-330.	5.7	84
53	The Tumor Suppressor PALB2: Inside Out. Trends in Biochemical Sciences, 2019, 44, 226-240.	3.7	83
54	GATA Factors and the Nuclear Receptors, Steroidogenic Factor 1/Liver Receptor Homolog 1, Are Key Mutual Partners in the Regulation of the Human 3Î²-Hydroxysteroid Dehydrogenase Type 2 Promoter. Molecular Endocrinology, 2005, 19, 2358-2370.	3.7	82

#	Article	IF	Citations
55	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
56	The Importance of Breast Adipose Tissue in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 5760.	1.8	82
57	Prostate cancer susceptibility genes: lessons learned and challenges posed.. Endocrine-Related Cancer, 2003, 10, 225-259.	1.6	81
58	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	0.9	81
59	New Insight into the Molecular Basis of 3Â-Hydroxysteroid Dehydrogenase Deficiency: Identification of Eight Mutations in the HSD3B2 Gene in Eleven Patients from Seven New Families and Comparison of the Functional Properties of Twenty-Five Mutant Enzymes. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4410-4425.	1.8	81
60	Association of Specific LDL Receptor Gene Mutations With Differential Plasma Lipoprotein Response to Simvastatin in Young French Canadians With Heterozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1007-1012.	1.1	80
61	Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genetics in Medicine, 2016, 18, 1190-1198.	1.1	80
62	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	2.6	76
63	BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Research, 2005, 8, R3.	2.2	75
64	Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis, 2000, 21, 189-193.	1.3	74
65	Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. Journal of Medical Genetics, 2006, 44, 107-121.	1.5	72
66	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
67	The Human Type II 17Î²-Hydroxysteroid Dehydrogenase Gene Encodes Two Alternatively Spliced mRNA Species. DNA and Cell Biology, 1995, 14, 849-861.	0.9	65
68	Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cellsin vitro. , 1997, 73, 104-112.		63
69	Congenital Adrenal Hyperplasia due to 3Î²-Hydroxysteroid Dehydrogenase/ Î”5-Î”4Isomerase Deficiency. Seminars in Reproductive Medicine, 2002, 20, 255-276.	0.5	59
70	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	2.6	59
71	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. Cancer Research, 2015, 75, 2457-2467.	0.4	55
72	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54

#	Article	IF	Citations
73	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	1.4	53
74	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	2.9	52
75	Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Human Genetics, 2005, 117, 119-132.	1.8	51
76	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	2.3	51
77	Adiposity, breast density, and breast cancer risk: epidemiological and biological considerations. European Journal of Cancer Prevention, 2017, 26, 511-520.	0.6	50
78	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	1.1	49
79	Factors Associated with an Individual's Decision to Withdraw from Genetic Testing for Breast And Ovarian Cancer Susceptibility: Implications for Counseling. Genetic Testing and Molecular Biomarkers, 2007, 11, 45-54.	1.7	48
80	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
81	Are ATM Mutations 7271Tâ†'G and IVS10-6Tâ†'G Really High-Risk Breast Cancer-Susceptibility Alleles?. Cancer Research, 2004, 64, 840-843.	0.4	47
82	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
83	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
84	Induction of 3Â-Hydroxysteroid Dehydrogenase/Â5-Â4 Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13. Molecular Endocrinology, 1999, 13, 66-81.	3.7	47
85	EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. Journal of Steroid Biochemistry and Molecular Biology, 2001, 79, 213-225.	1.2	46
86	Response of Symbiotic Endomycorrhizal Fungi to Estrogens and Antiestrogens. Molecular Plant-Microbe Interactions, 1997, 10, 481-487.	1.4	45
87	Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer, 2006, 6, 230.	1.1	45
88	No Evidence of BRCA1/2 Genomic Rearrangements in High-Risk French-Canadian Breast/Ovarian Cancer Families. Genetic Testing and Molecular Biomarkers, 2006, 10, 104-115.	1.7	45
89	Personalized medicine and access to health care: potential for inequitable access?. European Journal of Human Genetics, 2013, 21, 143-147.	1.4	45
90	Generation of a Transcription Map at the HSD17B Locus Centromeric to BRCA1 at 17q21. Genomics, 1995, 28, 530-542.	1.3	44

#	Article	IF	Citations
91	Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian Families with high risk of breast cancer. Journal of Human Genetics, 2009, 54, 152-161.	1.1	44
92	Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. Molecular and Cellular Endocrinology, 2001, 171, 25-40.	1.6	41
93	Life insurance: genomic stratification and risk classification. European Journal of Human Genetics, 2014, 22, 575-579.	1.4	41
94	A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. International Journal of Epidemiology, 2020, 49, 1117-1131.	0.9	41
95	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	3.0	40
96	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	1.4	40
97	Functional characterization of 84 PALB2 variants of uncertain significance. Genetics in Medicine, 2020, 22, 622-632.	1.1	40
98	Comparison of in vitro effects of the pure antiandrogens OH-flutamide, casodex, and nilutamide on androgen-sensitive parameters. Urology, 1997, 49, 580-589.	0.5	39
99	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	1.5	39
100	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
101	A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor. Nucleic Acids Research, 2019, 47, 10662-10677.	6.5	39
102	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	1.4	38
103	Synergistic Action of Prolactin (PRL) and Androgen on PRL-Inducible Protein Gene Expression in Human Breast Cancer Cells: A Unique Model for Functional Cooperation between Signal Transducer and Activator of Transcription-5 and Androgen Receptor. Molecular Endocrinology, 2002, 16, 1696-1710.	3.7	37
104	Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families. Journal of Human Genetics, 2008, 53, 579-591.	1.1	37
105	Association of the VariantsCASP8D302H andCASP10V410I with Breast and Ovarian Cancer Risk inBRCA1andBRCA2Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2859-2868.	1.1	37
106	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	2.6	37
107	Health Behaviors and Psychological Distress in Women Initiating BRCA1/2 Genetic Testing: Comparison with Control Population. Journal of Genetic Counseling, 2008, 17, 314-326.	0.9	35
108	Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites.. Journal of Medical Genetics, 1996, 33, 814-819.	1.5	34

#	Article	IF	Citations
109	Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2French Canadian families with high risk of breast cancer. BMC Cancer, 2009, 9, 181.	1.1	34
110	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
111	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
112	Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. Journal of Medical Genetics, 2018, 55, 97-103.	1.5	34
113	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 2016, 25, 3863-3876.	1.4	33
114	Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 1998, 65, 151-162.	1.2	32
115	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	1.4	32
116	Family Communication Following BRCA1/2 Genetic Testing: A Close Look at the Process. Journal of Genetic Counseling, 2013, 22, 323-335.	0.9	32
117	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	1.4	32
118	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
119	Glucocorticoids enhance activation of the human type II 3Î²-hydroxysteroid dehydrogenase/Î”5â€“Î”4 isomerase gene. Journal of Steroid Biochemistry and Molecular Biology, 2002, 82, 55-63.	1.2	31
120	Polymorphic variations in the FANCA gene in highâ€risk nonâ€BRCA1/2 breast cancer individuals from the French Canadian population. Molecular Oncology, 2013, 7, 85-100.	2.1	31
121	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 2016, 7, 80140-80163.	0.8	31
122	Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. International Journal of Cancer, 2019, 144, 1195-1204.	2.3	31
123	AURKAF31I Polymorphism and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1416-1421.	1.1	30
124	On the readiness of physicians for pharmacogenomics testing: an empirical assessment. Pharmacogenomics Journal, 2018, 18, 308-318.	0.9	30
125	Identification of a gene signature for different stages of breast cancer development that could be used for early diagnosis and specific therapy. Oncotarget, 2018, 9, 37407-37420.	0.8	30
126	The Role of Methylation in Breast Cancer Susceptibility and Treatment. Anticancer Research, 2015, 35, 4569-74.	0.5	30

#	Article	IF	Citations
127	Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Geneâ€Environment Interactions. Genetic Epidemiology, 2014, 38, 84-93.	0.6	28
128	Temporal analysis of E2 transcriptional induction of PTP and MKP and downregulation of IGF-I pathway key components in the mouse uterus. Physiological Genomics, 2007, 29, 13-23.	1.0	27
129	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	2.9	27
130	A Novel A10E Homozygous Mutation in the HSD3B2 Gene Causing Severe Salt-Wasting 3Â-Hydroxysteroid Dehydrogenase Deficiency in 46,XX and 46,XY French-Canadians: Evaluation of Gonadal Function after Puberty. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1968-1974.	1.8	27
131	Mapping of the HSD17B2 gene encoding type II 17Î²-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1â€“q24.2. Genomics, 1995, 25, 724-726.	1.3	26
132	Structure-function relationships and molecular genetics of the 3Î²-hydroxysteroid dehydrogenase gene family. Journal of Steroid Biochemistry and Molecular Biology, 1995, 55, 489-505.	1.2	26
133	Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians. Journal of Lipid Research, 2003, 44, 1508-1514.	2.0	26
134	The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 76-79.	1.1	26
135	Evaluation of the Contribution of the Three Breast Cancer Susceptibility Genes CHEK2, STK11, and PALB2 in Non-BRCA1/2 French Canadian Families with High Risk of Breast Cancer. Genetic Testing and Molecular Biomarkers, 2010, 14, 515-526.	0.3	26
136	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	1.1	26
137	Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families. Familial Cancer, 2007, 6, 483-490.	0.9	25
138	Machine learning analysis identifies genes differentiating triple negative breast cancers. Scientific Reports, 2020, 10, 10464.	1.6	25
139	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	1.1	24
140	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	1.1	24
141	Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells. Journal of Steroid Biochemistry and Molecular Biology, 2003, 87, 167-179.	1.2	23
142	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	1.1	23
143	Parallel solid-phase synthesis of a model library of 7Î±-alkylamide estradiol derivatives as potential estrogen receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2827-2832.	1.0	22
144	Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. Atherosclerosis, 1999, 143, 145-151.	0.4	22

#	Article	IF	Citations
145	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
146	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. British Journal of Cancer, 2014, 110, 1088-1100.	2.9	21
147	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	0.8	21
148	High risk genes predisposing to prostate cancer developmentâ€"do they exist?. Prostate Cancer and Prostatic Diseases, 2000, 3, 241-247.	2.0	20
149	A New Insight Into the Molecular Basis of 3Î²-Hydroxysteroid Dehydrogenase Deficiency. Endocrine Research, 2000, 26, 761-770.	0.6	20
150	Multiple signal transduction pathways mediate interleukin-4-induced 3Î²-hydroxysteroid dehydrogenase/Î”5â€“Î”4 isomerase in normal and tumoral target tissues. Journal of Steroid Biochemistry and Molecular Biology, 2001, 76, 213-225.	1.2	20
151	Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in highâ€risk non BRCA1/2 French Canadian breast and ovarian cancer families. International Journal of Cancer, 2008, 122, 108-116.	2.3	20
152	SNP-SNP interaction analysis of NF-ÎºB signaling pathway on breast cancer survival. Oncotarget, 2015, 6, 37979-37994.	0.8	20
153	Geneâ€"environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. International Journal of Cancer, 2017, 141, 1830-1840.	2.3	20
154	Epigenome-wide DNA methylation and risk of breast cancer: a systematic review. BMC Cancer, 2020, 20, 1048.	1.1	20
155	The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2009, 101, 1456-1460.	2.9	19
156	Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. Cancer Research, 2018, 78, 6329-6338.	0.4	19
157	Simultaneous quantification of estrogens and glucocorticoids in human adipose tissue by liquid-chromatography-tandem mass spectrometry. Journal of Steroid Biochemistry and Molecular Biology, 2019, 195, 105476.	1.2	19
158	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
159	Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. Advances in Protein Chemistry, 2001, 56, 293-368.	4.4	18
160	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
161	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
162	DNA Methylation and Breast Cancer Risk: An Epigenome-Wide Study of Normal Breast Tissue and Blood. Cancers, 2020, 12, 3088.	1.7	18

#	Article	IF	Citations
163	Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines. PLoS ONE, 2020, 15, e0234991.	1.1	18
164	Genetic linkage mapping of the human steroid 5α-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23→p22. Cytogenetic and Genome Research, 1996, 73, 304-307.	0.6	17
165	A focus group study on breast cancer risk presentation: one format does not fit all. European Journal of Human Genetics, 2013, 21, 719-724.	1.4	17
166	Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers. Frontiers in Genetics, 2017, 8, 128.	1.1	17
167	Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP1A1 gene and Dl 5S204 in the chromosome 15q22.33-q23 region. Pharmacogenetics and Genomics, 1998, 8, 49-53.	5.7	16
168	Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec. European Journal of Human Genetics, 2011, 19, 494-499.	1.4	16
169	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038.	1.1	16
170	The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. European Journal of Epidemiology, 2019, 34, 591-600.	2.5	16
171	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	2.9	15
172	Life Events may Contribute to Family Communication About Cancer Risk Following BRCA1/2 Testing. Journal of Genetic Counseling, 2013, 22, 249-257.	0.9	15
173	A new alternative splice variant of BRCA1 containing an additional in-frame exon. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2005, 1731, 57-65.	2.4	14
174	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	1.3	14
175	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. EBioMedicine, 2019, 48, 203-211.	2.7	14
176	A response to â€œPersonalised medicine and population health: breast and ovarian cancerâ€• Human Genetics, 2019, 138, 287-289.	1.8	14
177	Role of Secreted Frizzled-Related Protein 1 in Early Mammary Gland Tumorigenesis and Its Regulation in Breast Microenvironment. Cells, 2020, 9, 208.	1.8	14
178	17Î±-Hydroxylase/17,20-Lyase Deficiency Due to Novel Compound Heterozygote Mutations: Treatment for Tall Stature in a Female with Male Pseudohermaphroditism and Spontaneous Puberty in her Affected Sister. Journal of Pediatric Endocrinology and Metabolism, 2005, 18, 403-11.	0.4	13
179	Use of Dietary Supplements Among Women at High Risk of Hereditary Breast and Ovarian Cancer (HBOC) Tested for Cancer Susceptibility. Nutrition and Cancer, 2006, 54, 157-165.	0.9	13
180	Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. Journal of Molecular Endocrinology, 2008, 40, 161-172.	1.1	13

#	Article	IF	Citations
181	Analysis of 17Î²-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer. Journal of Steroid Biochemistry and Molecular Biology, 2009, 116, 134-153.	1.2	13
182	Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk. European Journal of Human Genetics, 2013, 21, 903-910.	1.4	13
183	Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk. International Journal of Cancer, 2020, 146, 2130-2138.	2.3	13
184	Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?. International Journal of Molecular Sciences, 2020, 21, 8613.	1.8	13
185	PALB2 Variants: Protein Domains and Cancer Susceptibility. Trends in Cancer, 2021, 7, 188-197.	3.8	13
186	Associations between markers of mammary adipose tissue dysfunction and breast cancer prognostic factors. International Journal of Obesity, 2021, 45, 195-205.	1.6	13
187	Multiple Signaling Pathways Mediate Interleukin-4-Induced 3Â-Hydroxysteroid Dehydrogenase/Â5-Â4 Isomerase Type 1 Gene Expression in Human Breast Cancer Cells. Molecular Endocrinology, 2000, 14, 229-240.	3.7	13
188	Partnering in Oncogenetic Research â€“ The INHERIT BRCAs Experience: Opportunities and Challenges. Familial Cancer, 2006, 5, 3-13.	0.9	12
189	Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer. Journal of Human Genetics, 2007, 52, 963-977.	1.1	12
190	No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. Breast Cancer Research and Treatment, 2009, 115, 185-192.	1.1	12
191	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	1.4	12
192	Analysis of a FANCE Splice Isoform in Regard to DNA Repair. Journal of Molecular Biology, 2015, 427, 3056-3073.	2.0	12
193	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	1.1	12
194	Organizational challenges to equity in the delivery of services within a new personalized risk-based approach to breast cancer screening. New Genetics and Society, 2019, 38, 38-59.	0.7	12
195	Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives. Healthcare Policy, 2019, 15, 39-54.	0.3	12
196	Genetic Linkage Mapping of the Dehydroepiandrosterone Sulfotransferase (STD) Gene on the Chromosome 19q13.3 Region. Genomics, 1995, 29, 781-783.	1.3	11
197	Self-reported mammography use following BRCA1/2 genetic testing may be overestimated. Familial Cancer, 2012, 11, 27-32.	0.9	11
198	Estrogens and Glucocorticoids in Mammary Adipose Tissue: Relationships with Body Mass Index and Breast Cancer Features. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1504-e1516.	1.8	11

#	Article	IF	Citations
199	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
200	The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes. Familial Cancer, 2016, 15, 1-17.	0.9	10
201	An isoform of AIF1 involved in breast cancer. Cancer Cell International, 2018, 18, 167.	1.8	10
202	Formation and degradation of dihydrotestosterone by recombinant members of the rat 3Î²-hydroxysteroid dehydrogenase/Î”5-Î”4 isomerase family. Molecular and Cellular Endocrinology, 1994, 103, 29-38.	1.6	9
203	Fine temporal analysis of DHT transcriptional modulation of the ATM/Gadd45g signaling pathways in the mouse uterus. Molecular Reproduction and Development, 2009, 76, 278-288.	1.0	9
204	Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study. Genetics in Medicine, 2012, 14, 60-68.	1.1	9
205	Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of QuÃ©bec (Canada). BMJ Open, 2018, 8, e016662.	0.8	9
206	PHIP- a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 2017, 8, 102769-102782.	0.8	9
207	Localization of BRCA1 Gene Expression in Adult Cynomolgus Monkey Tissues. Journal of Histochemistry and Cytochemistry, 1997, 45, 1173-1188.	1.3	8
208	Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer. Journal of Human Genetics, 2008, 53, 490-498.	1.1	8
209	Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2010, 122, 281-285.	1.1	8
210	Systematic mixed-methods reviews are not ready to be assessed with the available tools. Journal of Clinical Epidemiology, 2011, 64, 926-928.	2.4	8
211	Functional analysis of promoter variants in KU70 and their role in cancer susceptibility. Genes Chromosomes and Cancer, 2012, 51, 1007-1013.	1.5	8
212	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Human Genetics, 2016, 135, 137-154.	1.8	8
213	Mass spectra alignment using virtual lock-masses. Scientific Reports, 2019, 9, 8469.	1.6	8
214	Association Between BMI and DNA Methylation in Blood or Normal Adult Breast Tissue: A Systematic Review. Anticancer Research, 2020, 40, 1797-1808.	0.5	8
215	TBC1D9: An Important Modulator of Tumorigenesis in Breast Cancer. Cancers, 2021, 13, 3557.	1.7	8
216	Transcriptional signature of lymphoblastoid cell lines ofBRCA1,BRCA2and non-BRCA1/2high risk breast cancer families. Oncotarget, 2017, 8, 78691-78712.	0.8	8

#	Article	IF	Citations
217	Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. Journal of Steroid Biochemistry and Molecular Biology, 2008, 109, 115-128.	1.2	7
218	Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004â€“2014 in the U.S.: Further Evidence of the â€œAngelina Jolie Effectâ€?. American Journal of Preventive Medicine, 2017, 53, e195-e196.	1.6	7
219	Gene signatures of breast cancer development and the potential for novel targeted treatments. Pharmacogenomics, 2020, 21, 157-161.	0.6	7
220	Open science precision medicine in Canada: Points to consider. Facets, 2019, 4, 1-19.	1.1	7
221	Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families. Journal of Human Genetics, 2013, 58, 59-66.	1.1	6
222	SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation. Genetic Epidemiology, 2015, 39, 406-414.	0.6	6
223	Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation. Genetics in Medicine, 2016, 18, 627-634.	1.1	6
224	Genome-wide methylation analysis ofDNMT3Bgene isoforms revealed specific methylation profiles in breast cell lines. Epigenomics, 2016, 8, 1209-1226.	1.0	6
225	ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry. PLoS ONE, 2016, 11, e0156820.	1.1	5
226	Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 425-427.	1.1	5
227	Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?. Familial Cancer, 2017, 16, 35-40.	0.9	5
228	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	2.9	5
229	Association of Breast Tumour Expression of Cannabinoid Receptors CBR1 and CBR2 with Prognostic Factors and Survival in Breast Cancer Patients. Journal of Personalized Medicine, 2021, 11, 852.	1.1	5
230	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 136, 295-302.	1.1	4
231	Associations of Biomarkers of Inflammation and Breast Cancer in the Breast Adipose Tissue of Women with Combined Measures of Adiposity. Journal of Obesity, 2021, 2021, 1-10.	1.1	4
232	Characterization of the guinea pig 3Î²-hydroxysteroid dehydrogenase/Î”5â€“Î”4-isomerase expressed in the adrenal gland and gonads. Journal of Steroid Biochemistry and Molecular Biology, 2005, 97, 289-298.	1.2	3
233	Using the Impact of Event Scale to Evaluate Distress in the Context of Genetic Testing for Breast Cancer Susceptibility. Psychological Reports, 2006, 98, 873-881.	0.9	3
234	The CYP17A1 â^'34TÂ>ÂC polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2011, 126, 521-527.	1.1	3

#	Article	IF	Citations
235	Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers. Canadian Association of Radiologists Journal, 2016, 67, 308-312.	1.1	3
236	No Evidence of Excessive Cancer Screening in Female Noncarriers from BRCA1/2 Mutationâ€“Positive Families. Current Oncology, 2017, 24, 352-359.	0.9	3
237	Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. International Journal of Epidemiology, 2019, 48, 1727-1730.	0.9	3
238	Secreted Frizzled-Related Protein 1 as a Biomarker against Incomplete Age-Related Lobular Involution and Microcalcificationsâ€™ Development. Cancers, 2020, 12, 2693.	1.7	3
239	Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction. Biostatistics, 2020, 21, 518-530.	0.9	3
240	Is Carboxypeptidase B1 a Prognostic Marker for Ductal Carcinoma In Situ?. Cancers, 2021, 13, 1726.	1.7	3
241	Association between alcohol consumption and DNA methylation in blood: a systematic review of observational studies. Epigenomics, 2022, 14, 793-810.	1.0	3
242	DNA methylation of circadian genes and markers of cardiometabolic risk in female hospital workers: An exploratory study. Chronobiology International, 2022, , 1-12.	0.9	2
243	Authorsâ€™ response: Associations of obesity and circulating insulin and glucose with breast cancer risk. International Journal of Epidemiology, 2019, 48, 1016-1017.	0.9	1
244	Survey of primary care physiciansâ€™ views about breast and ovarian cancer screening for true BRCA1/2 non-carriers. Journal of Community Genetics, 2020, 11, 205-213.	0.5	1
245	BRCA1 Gene Expression in Reproductive and Endocrine Tissues in Adult Cynomolgus Monkey. Annals of the New York Academy of Sciences, 1998, 839, 444-446.	1.8	0
246	Lessons learned and challenges posed in cancer genetics. Journal of Internal Medicine, 2013, 274, 396-398.	2.7	0
247	Abstract P5-06-11: Secreted frizzled related protein 1: From lobular involution to breast osteoimmunological disorder. Cancer Research, 2022, 82, P5-06-11-P5-06-11.	0.4	0